Q2 26 EPS
$0.56
BEAT +52.51%
Est. $0.37
Q2 26 Revenue
$2.96B
BEAT +5.88%
Est. $2.80B
vs S&P Since Q2 26
+8.1%
BEATING MARKET
BAX +12.4% vs S&P +4.3%
Market Reaction
Did BAX Beat Earnings? Q2 2026 Results
Baxter International delivered a notably strong second quarter, with adjusted diluted EPS of $0.56 coming in 52.51% above the $0.37 consensus estimate and revenue of $2.96 billion beating expectations by 5.88% while growing 5.3% year over year. The h… Read more Baxter International delivered a notably strong second quarter, with adjusted diluted EPS of $0.56 coming in 52.51% above the $0.37 consensus estimate and revenue of $2.96 billion beating expectations by 5.88% while growing 5.3% year over year. The headline beat was powered by broad-based sales momentum across all segments, with Medical Products & Therapies generating roughly $2.08 billion in revenue, up 7% on a reported basis, and Advanced Surgery posting particularly impressive 12% growth. A significant tailwind came from an IEEPA tariff refund contributing $0.11 per diluted share, a benefit that had not been factored into prior guidance. The strong performance came despite adjusted gross margin contracting to 38.6% from 40.7% a year earlier, reflecting higher-cost inventory and reclassified functional costs weighing on profitability. Analysts had been watching margin trajectory closely heading into the print, and management's confidence in the business is now reflected in a raised full-year 2026 outlook, with adjusted diluted EPS guidance lifted to $1.95 to $2.15 and organic sales growth now expected at 2% to 3%.
Key Takeaways
- • Drug Compounding and IV Solutions strength within Infusion Therapies & Platforms
- • Strong global demand for Advanced Surgery products with 12% organic growth
- • Patient Support Systems driving Care & Connectivity Solutions growth
- • IEEPA tariff refund contributing $0.11 per diluted share benefit
- • Growth across all segments and divisions in both U.S. and International markets
BAX Forward Guidance & Outlook
Baxter raised its full-year 2026 financial outlook: reported sales growth from continuing operations of 3% to 4% (previously flat to 1%), organic sales growth from continuing operations of 2% to 3% (previously approximately flat), and adjusted diluted EPS from continuing operations of $1.95 to $2.15 (previously $1.85 to $2.05). The raised guidance reflects stronger-than-expected operating performance and a benefit from an IEEPA tariff refund.
BAX YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
BAX Revenue by Segment
With YoY comparisons, source: SEC Filings
BAX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance.”
— Andrew Hider, Q2 2026 Earnings Press Release
BAX Earnings Trends
BAX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BAX EPS Trend
Earnings per share: estimate vs actual
BAX Revenue Trend
Quarterly revenue: estimate vs actual
BAX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $0.37 | $0.56 | +52.51% | $2.96B | +5.88% |
| Q1 26 BEAT | $0.31 | $0.36 | +15.90% | $2.70B | +3.27% |
| Q4 25 MISS FY | $0.54 | $0.44 | -17.80% | $2.97B | +5.28% |
| FY Full Year | — | $2.27 | — | $11.24B | — |
| Q3 25 BEAT | $0.60 | $0.69 | +15.40% | $2.84B | -1.47% |
| Q2 25 MISS | $0.61 | $0.59 | -3.12% | $2.81B | -0.45% |